Lixisenatide: difference between revisions
Diff·revision 12 → 13·10:49, 22 May 2025
Difference between revision 12 and revision 13 of Lixisenatide. 7 lines changed; the page grew by 819 bytes.
| Revision 12 — 06:56, 23 Apr 2025 SemaglutideSasha (talk) fix the anchor on an internal link 3,215 bytes ±0 | Revision 13 — 10:49, 22 May 2025 StubSorterBot (talk) bot: normalise citation format 4,034 bytes +819 | ||
|---|---|---|---|
| 28 | The practical discipline this supports is to attribute outcome findings to the trial that produced them rather than to the class. See [[GLP-1 receptor agonist]].{{r|pfeffer2015}} | 28 | The practical discipline this supports is to attribute outcome findings to the trial that produced them rather than to the class. See [[GLP-1 receptor agonist]].{{r|pfeffer2015}} |
| 29 | 29 | ||
| + | 30 | == Current position == | |
| + | 31 | Lixisenatide has been largely displaced by weekly agents with larger effects and simpler administration, and by fixed combinations with basal insulin in which its postprandial action complements the basal agent.{{r|drucker2018}} | |
| + | 32 | ||
| + | 33 | It is not commonly encountered in research-chemical supply relative to the weekly analogues, which reflects demand rather than any property of the molecule.{{r|reports}} As a 44-residue exendin derivative it presents the ordinary synthetic-peptide characterisation problem.{{r|usp1503}} | |
| + | 34 | ||
| 30 | == References == | 35 | == References == |
| 31 | {{reflist}} | 36 | {{reflist}} |
| 32 | <ref name="pfeffer2015">Pfeffer MA, Claggett B, Diaz R, et al. "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome." ''New England Journal of Medicine'' 373(23):2247–2257 (2015). PMID 26630143.</ref> | 37 | <ref name="pfeffer2015">Pfeffer MA, Claggett B, Diaz R, et al. "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome." ''New England Journal of Medicine'' 373(23):2247–2257 (2015). PMID 26630143.</ref> |
| 33 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 38 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| + | 39 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| + | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 34 | 41 | ||
| 35 | == See also == | 42 | == See also == |